The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

manufacture and commercialize novel BNT327 combinations and next-generation bispecific antibodies Biotheus will become a new indirect Chinese subsidiary of BioNTech, adding a local research and ...

BioNTech SE (“BioNTech”) confirmed the completion of its acquisition of biotechnology company Biotheus for an upfront payment ...

The total consideration for Biotheus is $800 million, mainly in cash, plus performance-based payments of up to $150 million. BNT327 is a bispecific antibody that combines PD-L1 checkpoint ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platformfor the ...

BioNTech obtains full global rights to BNT327 and rights to all other candidates of Biotheus’ pipeline as well as to its in-house antibody generation platform and bispecific antibody drug ...